Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Clene Q3 2026 Results: Turns Profitable, Net Income $3.92M

Clene Inc. reported on its warrant status as of September 30, 2026, noting that Tranche A Warrants expired unexercised in June 2026, while Tranche B and 2024 Common Warrants remain outstanding with no exercises to date. The company continues to manage various debt instruments, including notes payable and convertible notes, while recording expenses related to R&D and general administrative operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.0
Profit before tax3.9-8.8
Net income3.9-8.8
EPS (diluted, $ a share)$0.05$-0.85

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+273.3%
Source

10-Q filed with the SEC, NASDAQ: CLNN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Clene Inc.: key numbers

Share price
$3.66Close, Nov 16
Market cap
$52.7M
Shares outstanding
14.4MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Clene Inc.

All →
8:38 AM ET 8-K
Financial Results

Clene Financial Results

Clene Inc. reported third quarter 2026 financial results, highlighting the submission of a New Drug Application (NDA) to the FDA for CNM-Au8 in ALS. The company ended the quarter with $9.9 million in cash, bolstered by a $4.0 million registered direct offering completed in September, providing a runway through mid-first quarter 2027.

“Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS. People living with ALS urgently need additional treatment options, and we appreciate the FDA’s constructive engagement throughout this process. We look forward to working closely with the Agency during its pending review. We believe CNM-Au8 has the capacity to restore and protect neuronal health and function and improve survival.”

Rob Etherington, President and CEO of Clene
6:02 AM ET 8-K
Business Update

Clene Business Update

Clene Inc. entered into a subaward amendment with NYU for the fourth year of a previously announced NIH grant, providing up to $7.2 million in funding. The grant supports an Expanded Access Program for the company's CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS). This represents the final year of a total $45.1 million four-year grant awarded under the ACT for ALS Act.

Counterparty
New York University
Term
Sept 2026 to Aug 2027
8:05 AM ET 8-K
Business Update

Clene Business Update

Clene Inc. has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS). The submission is based on neurofilament light chain biomarker data and clinical outcomes, with the company also preparing for a confirmatory Phase 3 RESTORE-ALS study.

Counterparty
FDA
5:13 PM ET 8-K
Capital Raise

Clene Capital Raise of $4M

Clene Inc. entered into a securities purchase agreement for a $4.0 million registered direct offering of 1,219,513 shares of common stock at $3.28 per share. The offering was led by the company's Chairman and CEO alongside existing investors to fund regulatory filings for its lead drug candidate, CNM-Au8, and general corporate purposes. The proceeds are expected to extend the company's cash runway through mid-first quarter 2027.

Value
$4M
Counterparty
David Matlin, Kensington Capital Holdings, and other existing stockholders

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.